Filing identity and reporting period
Important mismatch: The request identifies Processa Pharmaceuticals, Inc., but the supplied filing is Heatwurx, Inc.’s Form 10-K. This summary reflects the supplied filing, for the fiscal year ended December 31, 2014, not a Processa filing or a standalone 2014 fourth-quarter report. The 10-K was signed April 14, 2015.
Business context and financial results
Heatwurx develops asphalt-preservation and repair equipment using an infrared hot-in-place recycling process. It reported limited product sales and was focused on developing distribution, marketing, and service operations.
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $200,201 | $312,480 |
| Gross profit / margin | $86,950 / 43.4% | $124,478 / 39.8% |
| Operating loss | $(4,160,443) | $(2,961,320) |
| Net loss | $(4,526,250) | $(3,068,701) |
| Net loss attributable to common stockholders | $(6,029,141) | $(3,090,003) |
| Cash used in operating activities | $(2,695,448) | $(2,538,769) |
Equipment-sales revenue fell to $101,119 from $253,463; service revenue rose to $92,962 from $25,000. Gross margin improved despite lower revenue, but losses widened. FY 2014 results included an $822,205 debt-extinguishment loss and $390,659 goodwill impairment; interest expense also increased to $365,956 from $109,725. Fourth-quarter 2014 revenue was $14,400 and net loss was $1,538,804.
Liquidity, debt, and financial position
At December 31, 2014, cash was $21,234, current assets were $379,209, current liabilities were $840,053, total assets were $2,542,052, and total liabilities were $1,334,119. The company reported a $12,905,124 accumulated deficit. Cash declined from $186,864 at year-end 2013. Management estimated monthly spending at approximately $290,000 and stated that at least $3.5 million of additional funding was needed for the following 12 months.
Year-end debt included $229,980 under a revolving credit line, $160,000 of senior secured notes, $380,232 of unsecured notes net of discount, and $190,320 of equipment loans. The company also had $1,055,433 in disclosed contractual cash obligations, including lease and debt payments. It relied on private placements and loans from a small group of investors, many related to the company.
Material changes, outlook, and risks
- Revenue declined about 36% year over year, mainly because of fewer equipment sales; service revenue increased.
- In 2014, Heatwurx acquired Dr. Pave, a service business controlled by its CEO, and organized a subsidiary to offer franchises. Goodwill from the acquisition was immediately impaired.
- The company described a 2015 shift toward sales and marketing, licensed partners, consumables, and expanded distribution. It cited a five-year repair warranty and an insured repair guarantee, but provided no quantified sales or earnings guidance.
- The independent auditor’s report and management disclosures raised substantial doubt about the company’s ability to continue as a going concern. Continued operations depended on raising capital; management cautioned that financing might not be available on acceptable terms or at all.
- Subsequent to year-end, the company entered into a secured loan facility of up to $2 million at 12% interest, secured by company assets, including intellectual property. The filing lists $470,000 funded by April 8, 2015, while another passage says $450,000 had been raised by that date.
- Other significant risks include a single equipment manufacturer without a formal manufacturing agreement, customer and supplier concentration (two customers represented 53% of revenue; two suppliers accounted for 95% of equipment purchases), competitive and commercialization challenges, potential dilution, and concentrated ownership.
- Management reported ineffective disclosure controls and internal control over financial reporting due to a material weakness involving inadequate accounting personnel. Remediation was planned for 2015.
Most important facts for investors to verify
- Confirm the issuer and filing: the supplied document is Heatwurx, Inc.’s 2014 Form 10-K, not Processa Pharmaceuticals, Inc.’s filing.
- Reconcile the disclosed April 2015 funding amounts ($450,000 versus $470,000) and verify subsequent financing, maturities, collateral, and liquidity.
- Assess whether sales, service revenue, and distribution arrangements can support the cost base, and whether the stated warranty and insured guarantee are contractually supported.
- Review related-party lending and the CEO-controlled Dr. Pave acquisition, including terms, approvals, and potential conflicts.
- Track remediation of the material weakness and the auditor’s going-concern warning, as well as potential dilution from outstanding options and warrants.